GlobeNewswire Inc.··Adagene Inc.Adagene Posts Promising ADG126 Data With $74.5M Cash Runway Into 2028
Adagene reports 29% response rate for ADG126 in colorectal cancer with improved safety profile. Company maintains $74.5M cash reserves extending runway into early 2028.
MRKSNYRHHBYADAGcolorectal cancerclinical trial